CRISPR Therapeutics
Develops genome-editing medicines across blood disorders, liver targets, autoimmune disease, and diabetes.
$57.50
After-hours close−0.20 (−0.35%)
At close$57.70(−2.81%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 85.67%82.62M sharesInsiders 0.52%498.4K sharesOther 13.81%13.33M shares
Shares outstanding 96.45M · Float 96.04M · 99.6% free float
Institutions13F, as of Jun 30, 2026
556 holders · 82.62M shares · 83 new positions · 240 increased · 144 reduced · 54 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ark Investment Management LLC | 9.46M | 9.81% | −1.85M | Aug 14, 2026 |
| BlackRock, Inc. | 8.35M | 8.66% | +668.9K | Aug 7, 2026 |
| Orbis Allan Gray Ltd | 5.45M | 5.65% | −656.9K | Aug 14, 2026 |
| Capital World Investors | 4.75M | 4.92% | +24.5K | Aug 12, 2026 |
| State Street Corp | 4.32M | 4.48% | +339.2K | Aug 7, 2026 |
| GSK PLC | 3.22M | 3.34% | 0 | Aug 13, 2026 |
| Geode Capital Management, LLC | 2.51M | 2.60% | +132.8K | Aug 12, 2026 |
| T. Rowe Price Investment Management, Inc. | 2.05M | 2.13% | −899.6K | Aug 14, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARK Investment Management LLC | 11.79% | 11.31M | 13G | Apr 30, 2026 ↗ |
| BlackRock, Inc. | 6.90% | 5.93M | 13G | Jul 17, 2025 ↗ |
| Orbis Investment Management Ltd | 6.30% | 6.09M | 13G | May 15, 2026 ↗ |
| Capital World Investors | 5.10% | 4.93M | 13G | May 14, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Samarth Kulkarni | director, officer: Chief Executive Officer | 255.5K | 0.26% | Mar 24, 2026 |
| James R. Kasinger | officer: General Counsel and Secretary | 94.3K | 0.10% | Mar 24, 2026 |
| Simeon George | director | 69.7K | 0.07% | Jul 17, 2025 |
| Douglas A. Treco | director | 22.0K | 0.02% | Aug 8, 2025 |
| Naimish Patel | officer: Chief Medical Officer | 19.4K | 0.02% | Jun 1, 2026 |
| Raju Prasad | officer: Chief Financial Officer | 14.8K | 0.02% | Aug 11, 2026 |
| Julianne Bruno | officer: Chief Operating Officer | 10.5K | 0.01% | Mar 24, 2025 |
| John Greene | director | 7.0K | 0.01% | Feb 28, 2025 |
| Briggs Morrison | director | 5.2K | 0.01% | Jun 10, 2025 |
8 ten-percent owners hold 24.07M shares by Form 4, outside the officers-and-directors figure above · 13 people have not refiled in the last 18 months (3.22M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 29, 2026 | Naimish Patelofficer: Chief Medical Officer | Sale | 3,786 | $55.62 | 19,357 |
| Mar 23, 2026 | Raju Prasadofficer: Chief Financial Officer | Sale | 3,708 | $46.78 | 15,565 |
| Mar 23, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 10,020 | $46.78 | 255,501 |
| Mar 23, 2026 | James R. Kasingerofficer: General Counsel and Secretary | Sale | 3,182 | $46.78 | 94,308 |
| Mar 16, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 10,349 | $48.26 | 245,834 |
| Mar 16, 2026 | James R. Kasingerofficer: General Counsel and Secretary | Sale | 3,450 | $48.26 | 91,240 |
| Mar 16, 2026 | Raju Prasadofficer: Chief Financial Officer | Sale · 2 lots | 9,869 | $48.26 | 13,773 |
| Mar 16, 2026 | Naimish Patelofficer: Chief Medical Officer | Sale | 3,150 | $48.26 | 13,143 |
| Mar 11, 2026 | Samarth Kulkarnidirector, officer: Chief Executive Officer | Sale | 9,798 | $52.80 | 235,558 |
| Mar 11, 2026 | James R. Kasingerofficer: General Counsel and Secretary | Sale | 2,800 | $52.80 | 87,815 |
CongressHouse and Senate disclosures
Not reported.